Abstract: Methods and compositions for pulmonary delivery of chemically modified G-CSF, and pegylated proteins are disclosed.

Abstract: Therapeutically useful proteins are conjugated to vitamin B.sub.12 by covalent binding at the primary hydroxyl site of the ribose moiety. The resulting conjugates are biologically active and can be formulated into pharmaceutical compositions suitable for delivery by various routes of administration, preferably oral. Uptake in the gut following oral delivery is further enhanced by the co-administration of purified intrinsic factor.

Abstract: Biological factors with enhanced biological activity are prepared by covalently linking a biomolecule to one or more chains of a synthetic polymer wherein the synthetic polymer is derived from the oxymethylene-oxyethylene part structure.

Abstract: The present invention relates to single and multiple layer collagen films that are useful for improved sustained release delivery of pharmaceuticals.

Abstract: Erythropoietin (EPO) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration of EPO in accordance with this invention results in significant elevation of red blood cell levels. EPO can be administered in this manner to medically treat or prevent anemia, as well as to treat or prevent other maladies related to erythropoiesis.

Abstract: Granulocyte-colony stimulating factor (G-CSF) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration in accordance with this invention results in significant elevation of the neutrophil levels that compares favorably with delivery by subcutaneous injection. G-CSF can be administered in this manner to medically treat neutropenia, as well as to combat or prevent infections.

Abstract: The present invention consists of chelating agents for the treatment of iron overload and methods of using these agents in mammals such as mice and rats. These agents or compositions comprise diesters of dicarboxylic acids, which are phenolic derived and otherwise resemble ethylene and propylenediamine diacetic acids.The acids are known as: HBED [N,N'-bis(2-hydroxybenzyl)ethylenediamine N,N-diacetic acid]; EHPG [ethylenediamine N,N'-bis(2-hydroxyphenylacetic acid)]; HBPD [N,N'- bis(2-hydoxybenzyl)propylenediamine-N,N'-diacetic acid]; HBHPD [N,N'- bis(2-hydroxybenzyl)-2-hydroxy-1,3-propylenediamine-N,N'-diacetic acid].Mineral acid addition salts are also included in the spirit of this invention. Such salts as sulfuric, hydrochloric and nitric may be utilized.In activity it has been found that the odd-numbered carbon atom esters, such a dimethyl and dipentyl, specially of HBED, are of highest activity, as well as the dipentyl ester of the HBPD.

Abstract: Homopolymers and copolymers of lactones are prepared by ring-opening polymerization of a mixture of lactones which includes a monolactone, such as .epsilon.-caprolactone, and a dilactone, such as bis-2,2-(.epsilon.-caprolacton-4-yl)propane, which is capable of forming crosslinks. The resulting polymers range from tough and partially crystalline to amorphous, elastomeric materials, depending on the monomer composition and proportions. Additionally, these polymers may be designed to achieve different degrees of permeability and rates of biodegradation. As such, they are useful for the controlled delivery of medicinal agents and as surgical aids and temporary artificial biomaterials such as skin substitutes and burn dressings.

Abstract: Compositions containing either poly(.epsilon.-caprolactone) or copolymers of .epsilon.-caprolactone with other lactones, together with a drug, when subdermally implanted in the body, provide a slow sustained release of the drug. The polymers may be designed to biodegrade during or subsequent to the depletion of the drug.